GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review - Summary - MDSpire

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

  • By

  • Paula Rodriguez-Otero

  • Niels W. C. J. van de Donk

  • Kodandaram Pillarisetti

  • Ingrid Cornax

  • Deeksha Vishwamitra

  • Kathleen Gray

  • Brandi Hilder

  • Jaszianne Tolbert

  • Thomas Renaud

  • Tara Masterson

  • Christoph Heuck

  • Colleen Kane

  • Raluca Verona

  • Philippe Moreau

  • Nizar Bahlis

  • Ajai Chari

  • February 2, 2024

  • 0 min

Share

Objective:

To explore GPRC5D as a potential therapeutic target for multiple myeloma (MM) and review the data on GPRC5D-targeting T-cell–redirecting agents in clinical development, emphasizing its significance in improving treatment outcomes.

Key Findings:
  • GPRC5D is highly expressed in MM cells and is minimally expressed in normal tissues, making it a promising target for T-cell redirection therapies, which could lead to more effective treatment strategies.
  • GPRC5D expression is independent of BCMA, allowing for potential combination therapies to address MM heterogeneity and improve patient outcomes.
  • Increased GPRC5D expression is associated with high-risk disease and poor prognosis, although causative relationships remain unproven, highlighting the need for further research.
Interpretation:

GPRC5D represents a novel target for immunotherapy in MM, with its selective expression in malignant cells suggesting potential for effective treatment strategies.

Limitations:
  • Lack of in vivo models to fully understand GPRC5D's signaling mechanisms and functions, which limits the ability to translate findings into clinical practice.
  • Insufficient high-quality immunohistochemistry reagents for accurate GPRC5D detection in tissues, impacting the reliability of expression profiling.
Conclusion:

GPRC5D's unique expression profile in MM cells positions it as a valuable target for new therapeutic approaches, potentially improving outcomes for patients with this complex malignancy, warranting further investigation.

Original Source(s)

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

  • by Paula Rodriguez-Otero, Niels W. C. J. van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Philippe Moreau, Nizar Bahlis, Ajai Chari

  • February 2, 2024

Related Content

AstraZeneca Deepens China Cell Therapy Push

New Shanghai manufacturing base and innovation center will support CAR-T production and a broader UK-China life sciences collaboration

  • March 31, 2026

  • 2 min
Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders

Patient Awareness, Attitudes, and Preventive Practices Related to Venous Thromboembolism in Multiple Myeloma: A Cross-Sectional Analysis